Short Interest in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) Increases By 190.9%

Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totaling 135,284 shares, a growth of 190.9% from the July 15th total of 46,508 shares. Based on an average daily trading volume, of 95,778 shares, the short-interest ratio is currently 1.4 days.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC acquired a new position in Drugs Made In America Acquisition II during the 4th quarter worth approximately $265,000. Virtu Financial LLC acquired a new stake in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $317,000. ABC Arbitrage SA acquired a new stake in Drugs Made In America Acquisition II in the fourth quarter valued at approximately $396,000. Deltec Asset Management LLC bought a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter worth $495,000. Finally, Royal Bank of Canada bought a new stake in shares of Drugs Made In America Acquisition II during the fourth quarter worth $655,000.

Drugs Made In America Acquisition II Stock Down 0.0%

Shares of DMII stock traded down $0.01 on Thursday, hitting $10.12. 5,125 shares of the company’s stock were exchanged, compared to its average volume of 114,100. Drugs Made In America Acquisition II has a 12 month low of $9.86 and a 12 month high of $10.20. The stock’s 50 day moving average is $10.09.

Wall Street Analyst Weigh In

Several equities analysts have commented on DMII shares. Wall Street Zen raised shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.